Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma - A phase II trial of the childhood liver tumour strategy group (SIOPEL)

European Journal of Cancer

Volumn 48, Issue 18, 2012, Pages 3456-3464

  Zsíros, József ^a   Brugières, Laurence ^b   Brock, Penelope ^c   Roebuck, Derek ^c   Maibach, Rudolf ^d   Child, Margaret ^e   Morland, Bruce ^f   Casanova, Michela ^g   Pariente, Daniele ^h   Paris, Claudia ⁱ   Camargo, Beatriz De ^j   Ronghe, Milind ^k   Zimmermann, Arthur ^l   Plaschkes, Jack ^m   Czauderna, Piotr ⁿ   Perilongo, Giorgio ^o  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d IBCSG Coordinating Center   (Switzerland)

^e Margaret Childs   (United Kingdom)

^f BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h BICÊTRE HOSPITAL   (France)

ⁱ HOSPITAL LUIS CALVO MACKENNA   (Chile)

^j IM IN JK) Inst Do C   (Brazil)

^k ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^l UNIVERSITY OF BERN   (Switzerland)

^m UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

ⁿ MEDICAL UNIVERSITY OF GDANSK   (Poland)

^o UNIVERSITY HOSPITAL OF PADOVA   (Italy)

more..

Author keywords

Camptothecin; Child; Clinical trial phase II; Hepatoblastoma; Irinotecan; Liver cancer

Indexed keywords

IRINOTECAN;

ABDOMINAL PAIN; ADOLESCENT; ANEMIA; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DEHYDRATION; DIARRHEA; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEPATOBLASTOMA; HUMAN; INFANT; INFECTION; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SCHOOL CHILD; SINGLE DRUG DOSE; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS, ALKYLATING; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DIARRHEA; FEMALE; HEPATECTOMY; HEPATOBLASTOMA; HUMANS; INFANT; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LUNG NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; PROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84869491003     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.06.023     Document Type: Article

References (36)

1. J. Pritchard, J. Brown, and E. Shafford Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: A successful approach - results of the first prospective study of the International Society of Pediatric Oncology J Clin Oncol 18 2000 3819 3828
2. J. Fuchs, J. Rydzynski, and D. Von Schweinitz Pretreatment prognostic factors and treatment results in children with hepatoblastoma: A report from the German Cooperative Pediatric Liver Tumor Study HB 94 Cancer 95 2002 172 182 (Pubitemid 34743496)
3. H.M. Katzenstein, W.B. London, and E.C. Douglass Treatment of unresectable and metastatic hepatoblastoma: A pediatric oncology group phase II study J Clin Oncol 20 2002 3438 3444
4. B. Haberle, I. Schmid, and U. Bode High dose chemotherapy does not improve the overall survival of children with hepatoblastoma Pediatr Blood Cancer 51 2008 53
5. G. Perilongo, R. Maibach, and E. Shafford Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma N Engl J Med 361 2009 1662 1670
6. J. Zsíros, R. Maibach, and E. Shafford Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study J Clin Oncol 28 2010 2584 2590
7. Perilongo G, Zsiros J. Childhood liver tumours. In: Stevens MCG, Caron HN, Biondi A, editors. Cancer in children. Oxford: Oxford University Press; 2011.
8. J. Fuchs, U. Bode, and D. Von Schweinitz Analysis of treatment efficiency of carboplatin and etoposide in combination with radical surgery in advanced and recurrent childhood hepatoblastoma: A report of the German Cooperative Pediatric Liver Tumor Study HB 89 and HB 94 Klin Padiatr 211 1999 305 309 (Pubitemid 29364773)
9. T. Matsunaga, F. Sasaki, and M. Ohira Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma Pediatr Surg Int 19 2003 142 146 (Pubitemid 36781539)
10. W.D. Cacciavillano, L. Brugières, and M. Childs Phase II study of high-dose cyclophosphamide in relapsing and/or resistant hepatoblastoma in children: A study from the SIOPEL group Eur J Cancer 40 2004 2274 2279 (Pubitemid 39348878)
11. M. Semerano, L. Brugieres, and J. Zsiros Relapses in hepatoblastoma patients: clinical characteristics and outcome: experience of the International Childhood Liver Tumour strategy Group - SIOPEL Pediatr Blood Cancer 53 2009 746
12. J. Zsíros, and L. Brugieres Salvage strategies A. Zimmermann, G. Perilongo, M. Malogolowkin, D. Von Schweinitz, Pediatric liver tumors 2011 Springer-Verlag Berlin Heidelberg 34 45
13. J. Thompson, W.C. Zamboni, and P.J. Cheshire Efficacy of systemic administration of Irinotecan against neuroblastoma xenografts Clin Cancer Res 3 1997 423 431 (Pubitemid 27158067)
14. W.L. Furman, C.F. Stewart, and C.A. Poquette Direct translation of a protracted Irinotecan schedule from a xenograft model to a phase I trial in children J Clin Oncol 17 1999 1815 1824 (Pubitemid 29269252)
15. M. Cosetti, L.H. Wexler, and E. Calleja Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience J Pediatr Hematol Oncol 24 2002 101 105 (Pubitemid 34150548)
16. H. Mugishima, T. Matsunaga, and K. Yagi Phase I study of irinotecan in pediatric patients with malignant solid tumors J Pediatr Hematol Oncol 24 2002 94 100 (Pubitemid 34150547)
17. T. Shitara, A. Shimada, and R. Hanada Irinotecan for children with relapsed solid tumors Pediatr Hematol Oncol 23 2006 103 110 (Pubitemid 43170531)
18. C.D. Turner, S. Gururangan, and J. Eastwood Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience Neuro Oncol 4 2002 102 108 (Pubitemid 34285064)
19. G. Vassal, I. Boland, and A. Santos Potent therapeutic activity of Irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice Int J Cancer 73 1997 156 163 (Pubitemid 27446004)
20. G. Vassal, F. Doz, and D. Frappaz A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors J Clin Oncol 21 2003 3844 3852 (Pubitemid 46606240)
21. G. Vassal, D. Couanet, and E. Stockdale Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: A joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group J Clin Oncol 25 2007 356 361 (Pubitemid 350002983)
22. G. Vassal, F. Giammarile, and M. Brooks A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: A European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG) Eur J Cancer 44 2008 2453 2460
23. S. Blaney, S.L. Berg, and C. Pratt A phase I study of Irinotecan in pediatric patients: A pediatric oncology group study Clin Cancer Res 7 2001 32 37 (Pubitemid 32110202)
24. L.R. Bomgaars, M. Bernstein, and M. Krailo Phase II trial of irinotecan in children with refractory solid tumors: A Children's Oncology Group Study J Clin Oncol 25 2007 4622 4627 (Pubitemid 350035322)
25. H. Bleiberg, and E. Cvitkovic Characterisation and clinical management of CPT-11 (Irinotecan)-induced adverse events: the European perspective Eur J Cancer 32 1996 S18 S23
26. J.R. Hecht Gastrointestinal toxicity of Irinotecan Oncology 12 1998 S72 S78
27. A.M. Langevin, D.T. Casto, and P.J. Thomas Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: A Pediatric Oncology Group study J Clin Oncol 16 1998 2494 2499 (Pubitemid 28309046)
28. J. O'Leary, and F.M. Muggia Camptothecins: A review of their development and schedules of administration Eur J Cancer 34 1998 1500 1508 (Pubitemid 28446329)
29. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
30. B. Zee, D. Melnychuk, J. Dancey, and E. Eisenhauer Multinomial phase II cancer trials incorporating response and early progression J Biopharma Stat 9 1999 351 363 (Pubitemid 29262953)
31. S. Dent, B. Zee, and J. Dancey Application of a new multinomial phase II stopping rule using response and early progression J Clin Oncol 19 2001 785 791 (Pubitemid 32119094)
32. H.M. Katzenstein, C. Rigsby, and P.H. Shaw Novel therapeutic approaches in the treatment of children with hepatoblastoma J Pediatr Hematol Oncol 24 2002 751 755 (Pubitemid 35448742)
33. R.D. Palmer, and D.M. Williams Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11) Med Pediatr Oncol 41 2003 78 80 (Pubitemid 41103263)
34. O. Ijichi, S. Ishikawa, and Y. Shinkoda Response of heavily treated and relapsed hepatoblastoma in the transplanted liver to single-agent therapy with irinotecan Pediatr Transplant 10 2006 635 638
35. M. Qayed, C. Powell, E.R. Morgan, M. Haugen, and H.M. Katzenstein Irinotecan as maintenance therapy in high-risk hepatoblastoma Pediatr Blood Cancer 54 2010 761 763
36. A.S. Pappo, E. Lyden, and P. Breitfeld Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group J Clin Oncol 25 2007 362 369 (Pubitemid 350002984)